A new study, published in Nature Communications, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new ‘long acting’ medicine for the prevention of malaria.
Every year, malaria afflicts hundreds of millions of people and kills hundreds of thousands of children. Despite considerable success in reducing the worldwide prevalence of malaria, its incidence in visitors to endemic areas has continued to rise steadily.
Currently, the best available prevention of malaria requires oral dosing of antimalarial tablets. Chronic oral dosing of these medicines has significant complications because healthy people need to strictly adhere to the medication in order for effective prophylaxis to occur.
The study, led by Pharmacologist Professor Andrew Owen and Materials Chemist Professor Steve Rannard, aimed to utilise nanotechnology to improve the delivery of an existing antimalarial drug via a novel injectable format that can maintain blood concentration of the drug for weeks or months following a single dose.
Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanomedicine is the application of nanotechnology to the diagnosis, prevention or treatment of disease in the human body.
Solid Drug Nanoparticles (SDNs) are a nanotechnology with favourable characteristics to enhance drug exposure and improve the treatment or prevention of several diseases, including HIV and malaria.
The Liverpool team have previously shown SDNs to be effective for oral delivery of drugs, but this is the first time they have shown benefits for a long-acting injectable (LAI) format. These particles have an approximate diameter that is 1/500th the width of a human hair, and once injected into the muscle, establish a drug depot that releases drug into the bloodstream over an extended period of time.
Through the use of this technology the trans-Atlantic research team developed an LAI version of a daily anti-malarial tablet (atovaquone) which provided prophylactic blood concentrations in mice for a period of 28 days. Moreover, mice injected with the nanomedicine were completely protected from the malaria parasite when exposed during this time, and since mice eliminate the drug much more rapidly in humans, a much longer duration of protection might be expected in people.
Impacting large numbers
Professor Rannard, said: “Although anti-malaria drugs exist they require individuals to take medication daily. Chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to preventative therapies.
“Our research seeks to remove the need for daily tablets and generate long-acting dosing technologies that may be able to provide therapeutic drug concentrations for months after a single administration. This would provide a clinically-relevant intervention that could readily impact large numbers of people and significantly prevent the transmission of malaria.”
Professor Owen, added “The ability of this nanomedicine to protect from infection by malaria may provide an additional tool in the global arsenal used to combat malaria in non-immune travellers and ultimately people who live in endemic areas of the world. Since atovaquone is already licenced for use in humans and the nanomedicine contains ingredients already used in other medicines, it could be enter clinical trials within a very short timescale”
“If other drugs can be manufactured in this way, in the longer term there is also potential for a long-acting combination therapy for malaria.”
The full study, entitled ‘Long-acting injectable atovaquone nanomedicines for malaria prophylaxis’, can be found here.
For further information about nano-medicine please listen to the University of Liverpool podcast featuring Professors Rannard and Owen which can be found here.
The Latest on: Solid Drug Nanoparticles
via Google News
The Latest on: Solid Drug Nanoparticles
- Solid Tumor Cancer Cures: Bio-Path Holdings May Hold the Key on April 16, 2019 at 11:53 am
We have a Phase II in CML, or chronic myeloid leukemia, that is open for enrollment and are working on an IND for a trial in solid tumors ... in apoptosis treatments. The drug uses the same technology ... […]
- Global Nano-drug Market Prospective Growth, Opportunities, Top Key Players and Forecast to 2025 on April 11, 2019 at 12:28 am
The global Nano-drug market is valued at million US$ in 2018 and will ... Polymeric Micelles Solid lipid Nanoparticles Microemulsion and Nanoemulsion Nanosuspension Market size ... […]
- Nano-drug Global Market Demand, Growth, Opportunities, Top Key Players and Forecast to 2025 on April 10, 2019 at 11:57 pm
Apr 11, 2019 (Heraldkeeper via COMTEX) -- WiseGuyRerports.com Presents "Global Nano-drug Market Insights ... forecast-to-2025 Market size by ProductLiposomes Polymeric Micelles Solid lipid ... […]
- Absolute Privacy - Kamagra Tablets Cheapest on April 3, 2019 at 11:01 pm
to by brings ability solid. Levels blood these potential and of maximizing for ... two new rise blood They be visual in but Drug Ande the in that his by and the tube regarding reduction useful ... […]
- Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies on March 29, 2019 at 4:09 am
The increasing global prevalence of human immunodeficiency virus (HIV) is estimated at 36.7 million people currently infected. Lifelong antiretroviral (ARV) drug combination dosing allows management ... […]
- In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain. on March 28, 2019 at 5:00 pm
CONTEXT: Solid lipid nanoparticles (SLN) are regarded as interesting drug delivery systems and their preparation techniques have gained a great deal of attention. OBJECTIVE: To evaluate the ... […]
- Vitamin E TPGS emulsified vinorelbine bitartrate loaded solid lipid nanoparticles (SLN) on December 14, 2018 at 6:15 am
The main objective of this research is the development and optimization of a solid lipid nanoparticle (SLN) structure that can encapsulate hydrophilic and thermolabile Vinorelbine bitartrate to ... […]
- How Solid Drug Nanoparticles Can Tackle Drug Adherence Issues on August 27, 2018 at 8:19 am
This article is based around a talk given by Professor Andrew Owen from The University of Liverpool, UK, at the NANOMED conference hosted by the NANOSMAT Society in Manchester on the 26-28 th June ... […]
- Technique uses nanoparticles to deliver oral medication on August 8, 2018 at 8:41 am
In nanomedicine, tiny particles are used to carry drugs to treat a variety of conditions, including cancer. They are commonly given intravenously, because solid nanoparticles don't absorb in a proper ... […]
via Bing News